These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

664 related articles for article (PubMed ID: 24008870)

  • 21. The mTORC2 complex regulates terminal differentiation of C2C12 myoblasts.
    Shu L; Houghton PJ
    Mol Cell Biol; 2009 Sep; 29(17):4691-700. PubMed ID: 19564418
    [TBL] [Abstract][Full Text] [Related]  

  • 22. mTORC1-S6K1 inhibition or mTORC2 activation improves hippocampal synaptic plasticity and learning in Angelman syndrome mice.
    Sun J; Liu Y; Tran J; O'Neal P; Baudry M; Bi X
    Cell Mol Life Sci; 2016 Nov; 73(22):4303-4314. PubMed ID: 27173058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A critical role for the mTORC2 pathway in lung fibrosis.
    Chang W; Wei K; Ho L; Berry GJ; Jacobs SS; Chang CH; Rosen GD
    PLoS One; 2014; 9(8):e106155. PubMed ID: 25162417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PRAS40 and PRR5-like protein are new mTOR interactors that regulate apoptosis.
    Thedieck K; Polak P; Kim ML; Molle KD; Cohen A; Jenö P; Arrieumerlou C; Hall MN
    PLoS One; 2007 Nov; 2(11):e1217. PubMed ID: 18030348
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted inhibition of mTORC2 prevents osteosarcoma cell migration and promotes apoptosis.
    Wang X; Lai P; Zhang Z; Huang M; Wang L; Yin M; Jin D; Zhou R; Bai X
    Oncol Rep; 2014 Jul; 32(1):382-8. PubMed ID: 24840134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. mTORC2 Signaling Regulates Nox4-Induced Podocyte Depletion in Diabetes.
    Eid S; Boutary S; Braych K; Sabra R; Massaad C; Hamdy A; Rashid A; Moodad S; Block K; Gorin Y; Abboud HE; Eid AA
    Antioxid Redox Signal; 2016 Nov; 25(13):703-719. PubMed ID: 27393154
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rictor/mTORC2 pathway in oocytes regulates folliculogenesis, and its inactivation causes premature ovarian failure.
    Chen Z; Kang X; Wang L; Dong H; Wang C; Xiong Z; Zhao W; Jia C; Lin J; Zhang W; Yuan W; Zhong M; Du H; Bai X
    J Biol Chem; 2015 Mar; 290(10):6387-96. PubMed ID: 25564616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autoregulation of the mechanistic target of rapamycin (mTOR) complex 2 integrity is controlled by an ATP-dependent mechanism.
    Chen CH; Kiyan V; Zhylkibayev AA; Kazyken D; Bulgakova O; Page KE; Bersimbaev RI; Spooner E; Sarbassov DD
    J Biol Chem; 2013 Sep; 288(38):27019-27030. PubMed ID: 23928304
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disentangling the signaling pathways of mTOR complexes, mTORC1 and mTORC2, as a therapeutic target in glioblastoma.
    Jhanwar-Uniyal M; Dominguez JF; Mohan AL; Tobias ME; Gandhi CD
    Adv Biol Regul; 2022 Jan; 83():100854. PubMed ID: 34996736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin.
    Zou Z; Chen J; Yang J; Bai X
    Curr Cancer Drug Targets; 2016; 16(4):288-304. PubMed ID: 26563881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma.
    Benavides-Serrato A; Lee J; Holmes B; Landon KA; Bashir T; Jung ME; Lichtenstein A; Gera J
    PLoS One; 2017; 12(4):e0176599. PubMed ID: 28453552
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
    Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
    Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma.
    Ahmed M; Hussain AR; Bavi P; Ahmed SO; Al Sobhi SS; Al-Dayel F; Uddin S; Al-Kuraya KS
    Carcinogenesis; 2014 Jul; 35(7):1564-72. PubMed ID: 24583924
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis.
    Farhan MA; Carmine-Simmen K; Lewis JD; Moore RB; Murray AG
    PLoS One; 2015; 10(8):e0135245. PubMed ID: 26295809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.
    Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M
    Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deletion of Rictor in neural progenitor cells reveals contributions of mTORC2 signaling to tuberous sclerosis complex.
    Carson RP; Fu C; Winzenburger P; Ess KC
    Hum Mol Genet; 2013 Jan; 22(1):140-52. PubMed ID: 23049074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. mTORC1 and JNK coordinate phosphorylation of the p70S6K1 autoinhibitory domain in skeletal muscle following functional overloading.
    Martin TD; Dennis MD; Gordon BS; Kimball SR; Jefferson LS
    Am J Physiol Endocrinol Metab; 2014 Jun; 306(12):E1397-405. PubMed ID: 24801387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathological hypertrophy amelioration by PRAS40-mediated inhibition of mTORC1.
    Völkers M; Toko H; Doroudgar S; Din S; Quijada P; Joyo AY; Ornelas L; Joyo E; Thuerauf DJ; Konstandin MH; Gude N; Glembotski CC; Sussman MA
    Proc Natl Acad Sci U S A; 2013 Jul; 110(31):12661-6. PubMed ID: 23842089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth.
    Koo J; Wang X; Owonikoko TK; Ramalingam SS; Khuri FR; Sun SY
    Oncotarget; 2015 Apr; 6(11):8974-87. PubMed ID: 25797247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.
    Guichard SM; Curwen J; Bihani T; D'Cruz CM; Yates JW; Grondine M; Howard Z; Davies BR; Bigley G; Klinowska T; Pike KG; Pass M; Chresta CM; Polanska UM; McEwen R; Delpuech O; Green S; Cosulich SC
    Mol Cancer Ther; 2015 Nov; 14(11):2508-18. PubMed ID: 26358751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.